Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
91.9M
-
Shares change
-
-817K
-
Total reported value, excl. options
-
$130M
-
Value change
-
-$2.09M
-
Number of buys
-
51
-
Number of sells
-
-64
-
Price
-
$1.42
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2025
135 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2025.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.9M shares
of 108M outstanding shares and own 84.76% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (14.3M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (9.63M shares), Vivo Capital, LLC (8.89M shares), VANGUARD GROUP INC (6.66M shares), BlackRock, Inc. (5.51M shares), Rock Springs Capital Management LP (4.77M shares), Decheng Capital LLC (4.04M shares), MILLENNIUM MANAGEMENT LLC (3.84M shares), MORGAN STANLEY (3.54M shares), and D. E. Shaw & Co., Inc. (2.8M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.